Pacira BioSciences, Inc. (PCRX)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	705.85	700.97	674.98	666.82	541.53	429.65
Revenue Growth (YoY)	2.25%	3.85%	1.22%	23.14%	26.04%	2.05%
Cost of Revenue	231.77	252.01	260.93	284.09	195.8	176.75
Gross Profit	474.08	448.96	414.05	382.73	345.73	252.9
Selling, General & Admin	329.3	294.1	269.44	254.52	199.35	193.52
Other Operating Expenses	6.47	-	-	-	42.91	-
Operating Expenses	412.1	351.39	326.73	311.8	255.81	201.38
Operating Income	61.97	97.57	87.32	70.93	89.92	51.52
Interest Expense	-18.64	-16.57	-20.31	-39.98	-31.75	-25.67
Interest & Investment Income	22.94	19.69	11.44	4.54	0.9	4.63
Other Non Operating Income (Expenses)	-6.51	-0.37	-0.19	-1.29	-0.07	1.23
EBT Excluding Unusual Items	59.76	100.32	78.28	34.21	59	31.71
Merger & Restructuring Charges	-3.06	-9.99	-3.07	-11.25	-	0.04
Impairment of Goodwill	-163.24	-163.24	-	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-10	-2.6	1.62
Asset Writedown	-	-	-	-26.13	-	-
Other Unusual Items	-0.01	9.81	-13.5	26.48	-	-13.28
Pretax Income	-106.55	-63.11	61.7	13.3	56.4	20.09
Income Tax Expense	20.91	36.45	19.75	-2.61	14.42	-125.43
Net Income	-127.46	-99.56	41.96	15.91	41.98	145.52
Net Income to Common	-127.46	-99.56	41.96	15.91	41.98	145.52
Net Income Growth	-	-	163.72%	-62.10%	-71.15%	-
Shares Outstanding (Basic)	46	46	46	46	44	43
Shares Outstanding (Diluted)	46	46	52	47	46	44
Shares Change (YoY)	-15.61%	-11.03%	11.69%	1.99%	4.46%	5.22%
EPS (Basic)	-2.77	-2.15	0.91	0.35	0.95	3.41
EPS (Diluted)	-2.81	-2.15	0.89	0.34	0.92	3.33
EPS Growth	-	-	160.68%	-63.04%	-72.37%	-
Free Cash Flow	117.07	178.75	139.49	115.2	79.85	39.23
Free Cash Flow Per Share	2.54	3.87	2.68	2.48	1.75	0.90
Gross Margin	67.16%	64.05%	61.34%	57.40%	63.84%	58.86%
Operating Margin	8.78%	13.92%	12.94%	10.64%	16.61%	11.99%
Profit Margin	-18.06%	-14.20%	6.22%	2.39%	7.75%	33.87%
Free Cash Flow Margin	16.59%	25.50%	20.67%	17.28%	14.74%	9.13%
EBITDA	151.96	176.36	162.9	151.93	118.47	71.42
EBITDA Margin	21.53%	25.16%	24.13%	22.78%	21.88%	16.62%
D&A For EBITDA	89.99	78.79	75.57	81	28.55	19.91
EBIT	61.97	97.57	87.32	70.93	89.92	51.52
EBIT Margin	8.78%	13.92%	12.94%	10.64%	16.61%	11.99%
Effective Tax Rate	-	-	32.00%	-	25.57%	-
Revenue as Reported	705.85	700.97	674.98	666.82	541.53	429.65

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q